In an 82-year-old woman with a 7-month history of worsening indigestion, upper abdominal bloating, early satiety, and gastric adenocarcinoma, which molecule is most likely to have decreased expression in the tumor cells?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

E-Cadherin (Epithelial Cadherins) Shows Decreased Expression in Gastric Adenocarcinoma

The answer is (B) Epithelial cadherins - this cell adhesion molecule demonstrates decreased expression in gastric adenocarcinoma cells, particularly in the diffuse histologic subtype, and functions as a tumor suppressor whose loss contributes to cancer progression and metastasis.

Molecular Basis for E-Cadherin Loss

E-cadherin is a critical cell adhesion molecule that maintains epithelial cell-cell contacts and tissue architecture. In gastric adenocarcinoma, loss of E-cadherin expression represents a fundamental molecular alteration that drives malignant transformation 1.

Key Evidence Supporting Decreased E-Cadherin:

  • Tumor suppressor function: E-cadherin acts as a tumor suppressor in gastric cancer, with its loss associated with increased tumor invasiveness and metastatic potential 1

  • Hereditary gastric cancer: Germline mutations in CDH1 (the gene encoding E-cadherin) cause hereditary diffuse gastric cancer (HDGC), establishing its critical role in preventing gastric malignancy 2

  • Histologic correlation: E-cadherin loss is particularly characteristic of diffuse-type gastric adenocarcinoma, one of the two major histologic subtypes 1

  • Prognostic significance: Reduced E-cadherin expression correlates with poor clinical outcomes and aggressive tumor behavior 1

Why Other Options Are Incorrect

The remaining molecular markers actually show increased (not decreased) expression in gastric adenocarcinoma:

  • Type IV collagenase (E): Matrix metalloproteinases that degrade basement membrane are upregulated to facilitate invasion
  • Vascular endothelial growth factor (F): Angiogenic factors increase to support tumor vascularization
  • Integrins (D): These adhesion molecules often show altered (typically increased) expression patterns
  • Cathepsin D (A) and heparin-binding FGF (C): Growth-promoting factors typically increase in malignancy

Clinical Context

In this 82-year-old woman presenting with classic symptoms of gastric cancer (indigestion, bloating, early satiety), the adenocarcinoma cells have undergone malignant transformation characterized by loss of normal epithelial architecture. E-cadherin loss is a hallmark of this process, enabling cancer cells to detach from their neighbors, invade through tissue planes, and metastasize - explaining her progressive symptoms over 7 months.

Molecular Testing Implications

While current guidelines emphasize testing for HER2, MSI/MMR, PD-L1, and CLDN18.2 in gastric adenocarcinoma for therapeutic decision-making 3, E-cadherin status remains fundamental to understanding tumor biology and hereditary cancer risk assessment 2.

References

Research

Gastric adenocarcinoma: pathomorphology and molecular pathology.

Journal of cancer research and clinical oncology, 2001

Guideline

gastric cancer, version 2.2025, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.